Phase 1 consisted of developing the machine learning model to identify potential protein–protein interface hotspots that could be viable as a drug target, using the cancer-associated EphB2-ephrinB2 protein complex (PDB code: 1KGY) for illustration. The gene discussed is EPHB2; the disease is cancer.